Significant biomarkers for the management of hepatocellular carcinoma

Yasuteru Kondo, Osamu Kimura, Tooru Shimosegawa

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)


Surveillance of hepatocellular carcinoma (HCC) is important for early detection. Imaging tests including computed tomography, magnetic resonance imaging and ultrasonography with or without various kinds of contrast medium are important options for detecting HCC. In addition to the imaging tests, various kinds of biomarkers including alpha-fetoprotein (AFP), lectin-bound AFP (AFP-L3) and protein induced by vitamin K absence or antagonist II (PIVKA-II) have been widely used to detect HCC and analyze treatment response. Recently, various kinds of novel biomarkers (proteins and miRNA) have been found to predict the malignancy potential of HCC and treatment response to specific therapies. Moreover, various combinations of well-established biomarkers and novel biomarkers have been tested to improve sensitivity and specificity. In practical terms, biomarkers that can be analyzed using peripheral blood samples might be more useful than immunohistochemical techniques. It has been reported that quantification of cytokines in peripheral blood and the analysis of peripheral immune subsets could be good biomarkers for managing HCC. Here, we describe the usefulness of and update well-established and novel biomarkers for the management of HCC.

Original languageEnglish
Pages (from-to)109-115
Number of pages7
JournalClinical Journal of Gastroenterology
Issue number3
Publication statusPublished - 2015 Jun 30


  • AFP
  • AFP-L3
  • MDSCs
  • Tregs
  • miRNA

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Significant biomarkers for the management of hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this